Bupivacaine Effectiveness and Safety in SABER® Trial

Completed · Phase 3 · Has a placebo group

Conditions studied: Postoperative Pain, Abdominal Surgery

In brief

This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication). SABER-Bupivacaine is designed to continuously deliver bupivacaine, a common local anesthetic, for a few days in order to treat local post-surgical pain. The purpose of this study is to investigate safety (side effects) associated with the use of SABER-Bupivacaine and how well it works in reducing pain and opioid-related side effects following various kinds of abdominal surgeries.

Key facts

Study ID

NCT01052012

Run by

Durect

People needed

331

Starts

2009-12-01

Expected to finish

2011-09-01

Last updated by the study team

2021-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be able to read and understand the consent form, provide written consent, complete trial-related procedures, and communicate with the trial staff
• Males and females, 18 years of age and older scheduled to undergo elective general abdominal surgery
• Patients must be healthy or have only mild systemic disease
• BMI < 45
• Patients must have ECG wave form within normal limits
• Female and male patients must agree to use medically acceptable method of contraception throughout the entire trial period and for 1 week after the trial participation is completed

You may not qualify if…

• Patients who are pregnant or lactating
• Patients undergoing emergency surgery (unless full consent is obtained and all screening procedures are completed prior to surgery)
• Significant concomitant surgical procedure
• History of multiple prior laparotomy procedures
• Cancer with known metastases pre-operatively, which are suspected to impact post-operative recovery or pain
• Planned formation of stoma during surgery or plans to undergo another laparotomy procedure within 30 days post-operatively
• Pre-operative evidence of sepsis or septic shock
• Pre-operative evaluation that suggests a surgery may preclude full closure of the incision(s)
• Patients with current or regular use of systemic steroids, anticonvulsants, antiepileptics, antidepressants, or monoamine oxidase inhibitors, who cannot be withdrawn from these medications
• Patients with current or regular use of drugs known to significantly prolong the QTc interval
• Patients with known hypersensitivity to local anesthetic agents of the amide type (e.g. lidocaine, bupivacaine)
• Patients with known hypersensitivity to morphine
• Patients with conditions contraindicated for use of opioids
• Patients with atrial fibrillation/flutter or other non-sinus rhythm (including paced rhythm); left bundle branch block (LBBB); or the following conditions: right bundle branch block (RBBB) in presence of a cardiac disease, significant cardiomyopathy, and myocardial infarction within last 6 months
• Patients with a serum creatinine level two times more than the local laboratory normal limit
• Patients who have received greater than 600 mg morphine equivalent daily dose for three or more days per week in the month prior to the surgical procedure
• Patients who are currently being treated with methadone, or history of methadone use within the previous 6 months
• Patients with known or suspected abuse of opioids or other illicit drugs
• Patients with known or suspected alcohol abuse
• Participation in another clinical trial at the same time or within 30 days of this trial
• Patients who, in the Investigator's opinion, should not participate in the trial or may not be capable of following the trial schedule for any reason

Where it is running

• DURECT Study Site — Birmingham, Alabama, United States
• DURECT Study Site — Florence, Alabama, United States
• DURECT Study Site — Mobile, Alabama, United States
• DURECT Study Site — Mobile, Alabama, United States
• DURECT Study Site — Montgomery, Alabama, United States
• DURECT Study Site — Sheffield, Alabama, United States
• DURECT Study Site — Arcadia, California, United States
• DURECT Study Site — Fontana, California, United States
• DURECT Study Site — Laguna Hills, California, United States
• DURECT Study Site — Pasadena, California, United States
• DURECT Study Site — Tampa, Florida, United States
• DURECT Study Site — Powder Springs, Georgia, United States
• DURECT Study Site — Indianapolis, Indiana, United States
• DURECT Study Site — Boston, Massachusetts, United States
• DURECT Study Site — Troy, Michigan, United States
• DURECT Study Site — Duluth, Minnesota, United States
• DURECT Study Site — New York, New York, United States
• DURECT Study Site — Durham, North Carolina, United States
• DURECT Study Site — Columbus, Ohio, United States
• DURECT Study Site — Hershey, Pennsylvania, United States
• DURECT Study Site — Houston, Texas, United States
• DURECT Study Site — Temple, Texas, United States
• DURECT Study Site — Woodville South, South Australia, Australia
• DURECT Study Site — Box Hill, Victoria, Australia
• DURECT Study Site — Ringwood East, Victoria, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.